Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 16/20 | 0.68 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4923529 | 0.91 | P2RY12 (0.81) | P2RY12PIK3R1PIK3CAMTOR | |
| SCHEMBL4898753 | 0.86 | P2RY12 (0.57) | P2RY12 | |
| SCHEMBL4936951 | 0.83 | P2RY12 (0.56) | P2RY12 | |
| SCHEMBL4922588 | 0.81 | P2RY12 (1.00) | P2RY12 | |
| SCHEMBL4924830 | 0.80 | P2RY12 (0.82) | P2RY12 | |
| SCHEMBL4896726 | 0.79 | P2RY12 (0.70) | P2RY12 | |
| SCHEMBL4895182 | 0.79 | P2RY12 (0.54) | P2RY12 | |
| SCHEMBL4924697 | 0.77 | P2RY12 (0.71) | P2RY12PIK3R1PIK3CAMTOR | |
| SCHEMBL4910234 | 0.77 | P2RY12 (0.58) | P2RY12PIK3R1PIK3CAMTOR | |
| SCHEMBL4915470 | 0.76 | P2RY12 (0.74) | P2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200475-A1 | 4-Piperazinothieno[2,3-D] Pyrimidine Compounds As Platelet Aggregation Inhibitors | PFIZER INC. | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200475-A1 | 4-Piperazinothieno[2,3-D] Pyrimidine Compounds As Platelet Aggregation Inhibitors | PF4, TBXA2R, P2RY4 | P2RY12 24/4885PIK3R1 1933/4885PIK3CA 350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.